Opinions of the company Valneva SENASDAQ: VALN) fell in trading in Europe after the French health authority Haute Autorité de santé (HAS) advised against using the company’s vaccine for COVID-19 as part of a broader protection measure.
However, the HAS recommended the use of the VidPrevtyn Beta vaccine from Sanofi ( SNY ) ( OTCPK:SNYNF )/ GSK ( GSK ) and Nuvaxovid from Novavax ( NVAX ) as boosters for those unable to receive the messenger RNA shot, which remains the only option. he likes.
“However, HAS does not include the use of Valneva’s VLA2001 vaccine in the primary vaccination course,” the official said.
“There is no clinical information or immunological information about the current differences. Therefore, it has not been preserved at this time,” Reuters report quoting Elisabeth Bouvet, president of the HAS vaccine department.
In June, Valneva (VALN) received EU approval for its COVID-19 vaccine, VLA2001, for the first vaccine for those aged 18 – 50. The US biotech Dynavax Technologies (NASDAQ: DVAX) partnered with Valneva (VALN) to supply the CpG 1018 adjuvant used in the vaccine.
Read: In August, the company shared the encouraging results of VLA2001 after the first dose of AstraZeneca’s (AZN) vaccine for COVID-19.